57例不可手术的Ⅲ期非小细胞肺癌的治疗及生存分析  

Treatment and survival analysis of 57 cases of inoperable stage-Ⅲ non-small cell lung cancer

作　　者：高伟生[1] 罗鹏飞[2] 陈刚[3] 陈晓明[2] 郑登云[1] 吴一龙[3] 

机构地区：[1]广东省人民医院肿瘤中心乳腺科,广州510100 [2]广东省人民医院肿瘤中心介入科,广州510100 [3]广东省人民医院肿瘤中心胸外科,广州510100

出　　处：《中国肿瘤临床与康复》2007年第2期136-138,共3页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：广东省人民医院科学研究基金(Y02089)

摘　　要：目的分析不可手术的Ⅲ期非小细胞肺癌的治疗方法及其对预后的影响。方法57例ⅢB期及ⅢA期不可手术切除的非小细胞肺癌患者,其中36例(ⅢA期9例,ⅢB期27例)行静脉化疗加胸部放疗(A组),21例(ⅢA期5例,ⅢB期16例)行支气管动脉灌注联合静脉化疗加胸部放疗(B组)。结果A、B组的中位无进展生存时间(TTP)分别为12.0和11.75个月(P=0.74);中位生存期(MST)分别为17.96及18.33个月(P=0.461),1,2,3年生存率分别为75.0%、29.1%、11.7%及76.2%、23.8%、4.8%,两组之间比较差异无显著性(均为P>0.05)。结论在静脉化疗联合胸部放疗的基础上合并支气管动脉灌注化疗,并不能显著性改善不可手术的Ⅲ期非小细胞肺癌患者的远期生存。Objective To observe the clinical efficacy of different treatments in inoperable stage-HI non-small cell lung cancer （NSCLC） and their influence on prognosis. Methods Thirty-six cases （9 cases stage ⅢA and 27 cases stage ⅢB ） were given intravenous chemotherapy and radiotherapy （ group A） , and other 21 cases（5 cases stage ⅢA and 16 cases stage ⅢB） were given BAI （bronchial artery infusion） combined with intravenous chemotherapy and radiotherapy（ group B）. Results The median time to progression in group A and group B was 12.0 and 11, 75 months respectively（ P = 0.74）. The median survival time of group A and group B was 17.96 and 18.33 months respectively（ P = 0. 461 ）. The one-, two- and three-years survival rates of group A and group B were 75.0% ,29.1%, 11.7% and 76.2% ,23.8% ,4.8% respectively（P 〉 0.05 ）. Conclusion On the basis of intravenous chemotherapy and radiotherapy, BAI cannot significantly improve the long-term survival of inoperable stage-Ⅲ NSCLC.

关 键 词：肺肿瘤/放射疗法 肺肿瘤/化学疗法 介入治疗 预后 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]